Infliximab a chimeric monoclonal antibody against TNF-α that has been introduced for patients with Crohn's disease, rheumatoid arthritis, psoriasis, juvenile chronic arthritis and more recently for BD patients who were resistant to standard treatment [1,2]. Here, TNF is linked to Crohn disease.